Pharmicell Co (XKRX:005690) Additional Paid-In Capital : ₩49,412 Mil(As of Mar. 2024)

View and export this data going back to 1988. Start your Free Trial

What is Pharmicell Co Additional Paid-In Capital?

Pharmicell Co's quarterly additional paid-in capital increased from Sep. 2023 (₩48,875 Mil) to Dec. 2023 (₩49,412 Mil) but then stayed the same from Dec. 2023 (₩49,412 Mil) to Mar. 2024 (₩49,412 Mil).

Pharmicell Co's annual additional paid-in capital increased from Dec. 2021 (₩188,414 Mil) to Dec. 2022 (₩193,621 Mil) but then declined from Dec. 2022 (₩193,621 Mil) to Dec. 2023 (₩49,412 Mil).

Pharmicell Co Additional Paid-In Capital Historical Data

The historical data trend for Pharmicell Co's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmicell Co Additional Paid-In Capital Chart

Pharmicell Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

188,413.78

193,621.38

49,412.24

Pharmicell Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															48,874.52	48,874.52	48,874.52	49,412.24	49,412.24

Pharmicell Co Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Pharmicell Co Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Pharmicell Co's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmicell Co (XKRX:005690) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmicell Co Ltd (XKRX:005690) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

12F Chungho B/D, 3-2 Nonhyun-dong Gangnam-gu, Seoul, KOR, 135-010

Website

http://www.pharmicell.com

Pharmicell Co Ltd is a biotechnology company, engages in the manufacturing of biopharmaceutical medicines in South Korea. Its biopharmaceutical business engages in the development and manufacture of stem cell therapeutic drugs and stem cell-based cosmetics and others. Its products under development include mesenchymal stem cell products, such as Cellgram_AMI, a heart disease drug; Cellgram_IS and Cellgram_SCI, which are brain/nerve disorder drugs; Cellgram_Lung, a pulmonary disease drug; Cellgram_LC, a liver disease drug; and Cellgram_ED and Cellgram_CLI for the treatment of graft-versus-host disease, kidney transplant, impotence, and critical lower limb ischemia.

Pharmicell Co (XKRX:005690) Headlines

No Headlines